Syntis Bio is unlocking the full therapeutic potential of the small intestine—the body’s nexus for metabolic control, digestion and drug absorption.
Our oral therapies harness the small intestine’s unique biology to address global healthcare challenges ranging from rare genetic disorders to the most prevalent conditions.
We are rapidly advancing a pipeline of drug candidates in multiple therapeutic areas, starting with obesity.
Backed by leading life sciences and strategic investors, Syntis is led by a highly accomplished founding team, board of directors and clinical advisory board.
We are united by a vision to transform treatment for obesity, diabetes and other disorders where the small intestine plays a key role.
